Skip to content

Comparative Effectiveness of Dry Cupping and Graston Techniques in Scapulocostal Syndrome.

Comparative Effectiveness of Dry Cupping and Graston Techniques in Office Workers With Scapulocostal Syndrome; A Randomised Clinical Trail

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07102355
Acronym
CMR = Compress
Enrollment
46
Registered
2025-08-03
Start date
2024-10-01
Completion date
2025-09-13
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scapulocostal Syndrome

Keywords

Scapulocostal Syndrome, Myofascilal pain syndrome,, Graston Technique, Dry Cupping Therapy, Cervical Range of Motion

Brief summary

The goal of this clinical trial is to check the comparative effectiveness of Graston Techniques and Dry cupping in Office Workers with Scapulocostal syndrome. The main questions it aims to answer are: 1. To evaluate the relative effectiveness of dry cupping and the Graston technique. 2. How well each technique reduces symptoms and enhances work productivity and functional outcomes. 3. To assess whether integrating either Graston Technique or Dry Cupping provides more beneficial effects than conventional treatment alone. 1\) Be divided into 2 Groups (Group A= Dry Cupping; B: Graston Techniques) 2) get the treatment for 4 weeks (3 days a week). 3) Receive the same conventional treatment.

Detailed description

This study aims to compare the effectiveness of Graston and Dry cupping in treating Scapulocostal syndrome in office workers, focusing on specific outcomes like pain severity, functional outcomes, and work productivity. This study will be a randomized clinical trial with a sample size of 46 participants with work-related SCS. The participants will be obtained by non-probability convenient sampling based on the inclusion and exclusion criteria. Participants will be randomly assigned into two groups, with 23 subjects in each group. Group A will receive dry cupping along with conventional therapy while Group B will receive IASTM along with conventional therapy.

Interventions

OTHERExperimental: Group A = Dry Cupping

Dry cupping, originating in Middle Eastern and Asian countries, gained popularity in the United States after the 2016 Summer Olympics. It has two main forms: wet and dry cupping. Wet cupping involves laceration of the skin, while dry cupping uses negative pressure to pull the skin into the cup. Cupping is used to reduce musculoskeletal or myofascial pain, with the most accepted mechanism being localized hyperemia, which improves microcirculation and promotes healing

OTHERExperimental: Group B = Graston Technique

Instrument-assisted soft tissue mobilization (IASTM), derived from Cyriax cross-friction massage, is a popular alternative to traditional manual therapy techniques, with its first controlled study published in 1997 (Seffrin & Gardiner-Shires, 2019) .The Graston Technique(GT), also known as instrument-assisted soft tissue mobilization (IASTM), is used by chiropractors, doctors, and therapists to alleviate pain and range-of-motion restrictions caused by musculoskeletal injuries and scar tissue. (McKivigan, J. M., & Tulimero, G. et al. , 2020) . The Graston technique, is also used to alleviate upper cervical pain.

Sponsors

University of Management and Technology Sialkot Pakistan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

A convenient sampling technique was used. Data collection was initiated after taking the content form, and then participants were divided into two groups by lottery: Group A and Group B. Group A was given Dry cupping, and Group B was given the Graston Technique along with Conventional Treatment.

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

1. 18-30 age group 2. Males and females 3. Office Workers. 4. Subjects that have symptoms of musculoskeletal nature ( 5. Subjects with pain lasting for longer than 3 months (

Exclusion criteria

1. Subjects with underlying pathology such as TOS, brachial neuralgia, cervical radiculopathy, polymyositis or Fibro myositis 2. Subjects with systemic diseases such as rheumatoid arthritis, ankylosing spondylitis 3. Subjects with the presence of any fractures 4. Heart/diabetic patients 5. Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Pain Intensity as Measured by the Visual Analog Scale4 WeeksPain intensity will be measured using the Visual Analog Scale (VAS), a 100 mm horizontal line anchored by two extremes: 0 mm represents no pain and 100 mm represents worst imaginable pain. Participants will mark the point that best represents their pain intensity. The score is the distance in millimeters from the left end to the mark. Change in pain intensity will be calculated by subtracting the Week 4 score from the baseline score. A decrease in VAS score indicates an improvement in pain levels.
Cervical Range of Motion (ROM)4 weeksCervical spine Range of Motion (ROM) will be assessed and measured using a universal goniometer by utilizing moving and stationary arm of angles in cervical spine range of motion..

Secondary

MeasureTime frameDescription
Neck Disability Index (NDI) Total Score4 WeeksThe Neck Disability Index (NDI) is a validated 10-item questionnaire assessing neck-specific disability. Each item is scored from 0 to 5, resulting in a total score range of 0 to 50. Higher scores indicate greater disability. The change in total NDI score from baseline to Week 4 will be calculated. A decrease in score indicates clinical improvement.
Treatment-Related Adverse Events During the 4-Week Intervention4 weeksTreatment-related adverse events (AEs), such as skin irritation, bruising, or discomfort, will be recorded throughout the study. The number of participants experiencing at least one AE will be counted. All AEs will be assessed for severity and relatedness to the intervention.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026